📇 Rhumatologue · EPAGNY METZ TESSY · (74) · Salarié

MME ALICE BEREZNE

Pourquoi vous devez consulter ce praticien

2 raisons identifiées

Auteur de référence en rhumatologie
34 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
131.5 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 EPAGNY METZ TESSY (74)SalariéRPPS 10001549095

🇫🇷 Publications académiques françaises (8)

✨ Génération du profil synthétique IA en cours…

Publications académiques en France

Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.

Janus kinase and calcineurin‐inhibitor combination in anti‐MDA5 dermatomyositis: No significant survival benefit but reassuring safety profile
2025
Article

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Scleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controls

Rheumatology (Oxford, England) · 2012

📚 117 citations🎯 RCR 4.53Top 9% NIH

Granulomatous disease in CVID: retrospective analysis of clinical characteristics and treatment efficacy in a cohort of 59 patients

Journal of clinical immunology · 2013

📚 107 citations🎯 RCR 4.02Top 11% NIH

Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients

British journal of haematology · 2011

📚 105 citations🎯 RCR 3.04Top 16% NIH🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

SummaryPatients with common variable immunodeficiency (CVID) are at high risk of developing immune thrombocytopenia (ITP) and/or autoimmune haemolytic anaemia (AHA). Given their underlying immunodeficiency, immunosuppressive treatment of these manifestations may increase the risk of infection. To assess efficacy and safety of rituximab in patients with CVID‐associated ITP/AHA, a multicentre retrospective study was performed. Thirty‐three patients, 29 adults and four children, were included. Patients received an average of 2·6 treatments prior to rituximab including steroids, intravenous immunoglobulin and splenectomy (21%). The median ITP/AHA duration at time of first rituximab administration was 12 months [range 1–324] and the indication for using rituximab was ITP (22 cases), AHA (n = 5) or both (n = 7); 1 patient was treated sequentially for ITP and then AHA. The overall initial response rate to rituximab was 85% including 74% complete responses. After a mean follow‐up of 39 ± 30 months after rituximab first administration, 10 of the initial responders relapsed and re‐treatment with rituximab was successful in 7/9. Severe infections occurred after rituximab in eight adults (24%), four of whom were not on immunoglobulin replacement therapy. In conclusion, rituximab appears to be highly effective and relatively safe for the management of CVID‐associated severe immune cytopenias.

Cookies & analyse de trafic

MME ALICE BEREZNE

Pourquoi vous devez consulter ce praticien

Publications académiques en France

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (34) — classées par pathologie

Transversal9

Sclérodermie6

Épidémiologie & registres3

Biothérapies non-anti-TNF2

IRM ostéo-articulaire2

Lupus2

Revue générale2

Vascularites2

Activité physique / Rééducation1

Biomarqueurs / Auto-Ac1

Corticothérapie1

csDMARDs1

Essai clinique1

Pharmacovigilance1

Qualité de vie / PROMs1

Santé mentale / fatigue1

Vascularites des gros vaisseaux1

Datasets & protocoles partagés

Partager cette fiche